Catalogo Articoli (Spogli Riviste)

OPAC HELP

Titolo:
VACCINE-INDUCED PROTECTION OF CHIMPANZEES AGAINST INFECTION BY A HETEROLOGOUS HUMAN-IMMUNODEFICIENCY-VIRUS TYPE-1
Autore:
GIRARD M; MEIGNIER B; BARRESINOUSSI F; KIENY MP; MATTHEWS T; MUCHMORE E; NARA PL; WEI Q; RIMSKY L; WEINHOLD K; FULTZ PN;
Indirizzi:
UNIV ALABAMA,SCH MED,DEPT MICROBIOL BIRMINGHAM AL 35294 UNIV ALABAMA,SCH MED,DEPT MICROBIOL BIRMINGHAM AL 35294 PASTEUR MERIEUX SERUMS & VACCINS F-69280 MARCY LETOILE FRANCE INST PASTEUR F-75015 PARIS FRANCE TRANSGENE SA F-67000 STRASBOURG FRANCE DUKE UNIV,MED CTR,DEPT SURG DURHAM NC 27710 NYU,MED CTR,EXPTL MED & SURG PRIMATES LAB NEW YORK NY 10016 NCI,FREDERICK CANC RES & DEV CTR FREDERICK MD 21701
Titolo Testata:
Journal of virology
fascicolo: 10, volume: 69, anno: 1995,
pagine: 6239 - 6248
SICI:
0022-538X(1995)69:10<6239:VPOCAI>2.0.ZU;2-2
Fonte:
ISI
Lingua:
ENG
Soggetto:
NEUTRALIZING MONOCLONAL-ANTIBODY; GP160 SUBUNIT VACCINE; ENVELOPE GLYCOPROTEIN; RECOMBINANT VACCINIA; T-CELLS; SYNTHETIC PEPTIDES; MONONUCLEAR-CELLS; HIV INFECTION; ENV PROTEIN; GP120;
Tipo documento:
Article
Natura:
Periodico
Settore Disciplinare:
Science Citation Index Expanded
Citazioni:
69
Recensione:
Indirizzi per estratti:
Citazione:
M. Girard et al., "VACCINE-INDUCED PROTECTION OF CHIMPANZEES AGAINST INFECTION BY A HETEROLOGOUS HUMAN-IMMUNODEFICIENCY-VIRUS TYPE-1", Journal of virology, 69(10), 1995, pp. 6239-6248

Abstract

The extraordinary genetic diversity of human immunodeficiency virus type 1 (HIV-1) is a major problem to overcome in the development of an effective vaccine, In the most reliable animal model of HIV-1 infection, chimpanzees were immunized with various combinations of HIV-1 antigens, which were derived primarily from the surface glycoprotein, gp160, of HIV-1 strains LAT and MN, The immunogens also included a live recombinant canarypox virus expressing a gp160-MN protein. In one experiment, two chimpanzees were immunized multiple times; one animal received antigens derived only from HIV-I-LAI and the second animal received antigens from both HIV-1(LAI) and HIV-1(MN). In another experiment, four chimpanzees were immunized in parallel a total of five times over 18 months; two animals received purified gp160 and V3-MN peptides, whereas the other two animals received the recombinant canarypox virus andgp160. At 3 months after the final booster, all immunized and naive control chimpanzees were challenged by intravenous inoculation of HIV-1(SF2); therefore, the study represented an intrasubtype B heterologousvirus challenge. Virologic and serologic follow-up showed that the controls and the two chimpanzees immunized with the live recombinant canarypox virus became infected, whereas the other animals that were immunized with gp160 and V3-MN peptides were protected from infection. Evaluation of both cellular and humoral HIV-specific immune responses at the time of infectious HIV-1 challenge identified the following as possible correlates of protection: antibody titers to the V3 loop of MN and neutralizing antibody titers to HIV-1(MN) or HIV-1(LAI) but not to HIV-1(SF2). The results of this study indicate that vaccine-mediated protection against intravenous infection with heterologous HIV-1 strains of the same subtype is possible with some immunogens.

ASDD Area Sistemi Dipartimentali e Documentali, Università di Bologna, Catalogo delle riviste ed altri periodici
Documento generato il 10/04/20 alle ore 01:16:37